Rapid and large-scale implementation of HCV treatment advances in France, 2007–2015

BACKGROUND: The last decade was marked by major advances in HCV treatment with the introduction of first wave protease inhibitors (1st-wave PIs, telaprevir or boceprevir) in 2011 and second direct-acting antivirals (2nd-wave DAAs) in 2014, that followed low effective pegylated interferon α / ribavir...

Descripción completa

Detalles Bibliográficos
Autores principales: Brouard, Cécile, Boussac-Zarebska, Marjorie, Silvain, Christine, Durand, Julien, de Lédinghen, Victor, Pillonel, Josiane, Delarocque-Astagneau, Elisabeth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5738822/
https://www.ncbi.nlm.nih.gov/pubmed/29262788
http://dx.doi.org/10.1186/s12879-017-2889-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5738822/
https://www.ncbi.nlm.nih.gov/pubmed/29262788
http://dx.doi.org/10.1186/s12879-017-2889-4

Ejemplares similares